Variantyx, a leader in high complexity hereditary disease testing, has secured $20M in funding for their Whole Genome Sequencing (WGS)-based testing methodology.

The series C funding round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, and 20/20 HealthCare Partners.

Variantyx is a CLIA/CAP laboratory providing Genomic Unity, a whole genome sequencing (WGS)-based testing program for diagnosis of rare inherited disorders. Its single method approach to comprehensive genetic testing identifies multiple variant types within a single patient sample to provide a unified clinical report.